TANK-binding kinase 1 (TBK1) is a serine/threonine kinase that plays central roles in innate immunity, autophagy, and cell survival. TBK1 is a critical regulator of type I interferon (IFN) signaling and selective autophagy, particularly mitophagy. Mutations in TBK1 cause a spectrum of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and hereditary spastic paraplegia (HSP), establishing TBK1 as an important therapeutic target.
| TANK-Binding Kinase 1 |
|---|
| Protein Name | TANK-binding kinase 1 |
| Gene | TBK1 |
| UniProt ID | Q9UHD2 |
| PDB IDs | 5W5V, 5WOJ, 6NAM |
| Molecular Weight | 84 kDa |
| Subcellular Localization | Cytoplasm, endosomes, mitochondria |
| Protein Family | IKK family, serine/threonine protein kinases |
| Associated Diseases | ALS, FTD, HSP, Herpes Encephalitis |
TBK1 is a 729-amino acid serine/threonine kinase that belongs to the IκB kinase (IKK) family. Originally characterized as a kinase activating NF-κB in response to tumor necrosis factor, TBK1 has emerged as a master regulator of multiple signaling pathways. The discovery of TBK1 mutations in ALS and FTD patients highlighted its importance in neuronal homeostasis. This comprehensive page covers TBK1's structure, normal functions, disease mechanisms, and therapeutic implications.
¶ Domain Architecture
TBK1 contains multiple functional domains:
-
Kinase domain (KD, residues 1-307): The catalytic domain at the N-terminus with serine/threonine kinase activity. Contains the activation loop with critical phosphorylation sites (S172).
-
Ubiquitin-like domain (ULD, residues 308-383): A helical domain that participates in dimerization and substrate recognition.
-
Coiled-coil domain 1 (CC1, residues 384-520): Mediates protein-protein interactions and dimerization.
-
Helical domain (HD, residues 521-600): Another dimerization motif.
-
Coiled-coil domain 2 (CC2, residues 601-650): Enables higher-order oligomerization and activation.
TBK1 exists as a dimer in solution. Activation requires:
- Autophosphorylation at S172: Within the activation loop
- Dimerization: Through CC1, HD, and CC2 domains
- Conformational changes: Induced by adaptor binding or phosphorylation
- Full activation: Additional phosphorylation events
- Phosphorylation: Multiple sites including S172 (activation), S15, T23
- Ubiquitination: K63-linked ubiquitination for signaling function
- SUMOylation: Modulates activity and localization
TBK1 is essential for antiviral immunity:
- RIG-I signaling: Activation of RIG-I-like receptors (RLRs) triggers MAVS aggregation, recruiting TBK1
- cGAS-STING pathway: Cytosolic DNA sensing activates cGAS, producing cGAMP, which activates STING and TBK1
- IRF3/7 phosphorylation: TBK1 phosphorylates IRF3 and IRF7, driving type I IFN transcription
- Canonical NF-κB pathway: TBK1 contributes to IKK activation downstream of multiple receptors
- Non-canonical pathway: Some evidence for TBK1 in non-canonical NF-κB signaling
TBK1 phosphorylates and activates autophagy receptors:
- OPTN/Optineurin: Phosphorylation enhances binding to LC3 and ubiquitin chains
- p62/SQSTM1: TBK1 phosphorylates p62, increasing its autophagy receptor function
- NDP52: Regulates mitophagy receptor function
- TBK1 is recruited to damaged mitochondria
- Phosphorylates mitophagy receptors (OPTN, NDP52, CALCOCO2)
- Coordinates mitochondrial clearance with innate immune signaling
¶ Cell Survival and Growth
- NF-κB-dependent survival signaling
- mTORC1 regulation: TBK1 can activate mTORC1 signaling
- Metabolic regulation: Links nutrient sensing to autophagy
TBK1 is widely expressed in various tissues with high expression in:
- Brain: Neurons, astrocytes, microglia
- Immune cells: Macrophages, dendritic cells, NK cells
- Lung: Alveolar epithelial cells
- Heart: Cardiomyocytes
- Liver: Hepatocytes
In the nervous system, TBK1 is expressed in:
- Motor neurons of the spinal cord
- Cortical pyramidal neurons
- Dopaminergic neurons in substantia nigra
- Microglial cells
Over 150 TBK1 mutations have been identified in ALS/FTD:
- Missense mutations: Many in the kinase domain or protein-protein interaction domains
- Loss-of-function mutations: Frameshift, nonsense mutations causing haploinsufficiency
- ALS-FTD overlap: ~50% of TBK1 mutation carriers develop both diseases
| Mutation Type |
Examples |
Effect |
| Missense |
E696K, R47H, R444X |
Variable functional impact |
| Nonsense |
Q446X, R444X |
Premature termination |
| Frameshift |
617delC, 1915-1916del |
Truncated protein |
-
Impaired mitophagy:
- Defective clearance of damaged mitochondria
- Accumulation of dysfunctional mitochondria in motor neurons
- Increased oxidative stress
-
Dysregulated innate immune signaling:
- Altered IFN responses
- Chronic neuroinflammation
- Enhanced inflammatory cytokine production
-
Synaptic dysfunction:
- Impaired synaptic autophagy
- Disrupted neuronal connectivity
-
Autophagy defects:
- General autophagy impairment
- Protein aggregate accumulation
- FTD-TDP pathology: TBK1 mutations associated with TDP-43 pathology
- Autosomal dominant inheritance: Some families show dominant transmission
- Phenotypic heterogeneity: Variable presentation within families
- Overlap with ALS: Common genetic and pathological features
- SPG31: TBK1 mutations cause this autosomal recessive HSP
- Pure and complicated forms: Some patients have additional neurological features
- Primary symptom: Progressive lower limb spasticity
TBK1 interacts with several key proteins relevant to neurodegeneration:
- OPTN/Optineurin: Primary substrate; phosphorylation enhances mitophagy
- p62/SQSTM1: Autophagy receptor phosphorylated by TBK1
- STING/TMEM173: Innate immune adaptor in cGAS-STING pathway
- MAVS: Mitochondrial antiviral signaling protein
- IRF3/IRF7: Transcription factors activated by TBK1
- IKKε: Homologous kinase with overlapping functions
- NEMO/IKKγ: NF-κB regulatory subunit
- TBK1 knockout mice: Embryonic lethal, demonstrating essential function
- Conditional knockouts: Neuron-specific deletion
- Mutant knock-in: Modeling patient mutations
- Transgenic models: Overexpression of mutant TBK1
- Motor neuron-specific TBK1 loss causes progressive motor deficits
- Impaired mitophagy in neurons
- Neuroinflammation in TBK1-deficient mice
- Synaptic dysfunction precedes neurodegeneration
| Compound |
Mechanism |
Development Stage |
| BX795 |
TBK1/IKKε inhibitor |
Research |
| Amlexanox |
TBK1/IKKε inhibitor |
Clinical (asthma) |
| MRT67307 |
TBK1/IKKε inhibitor |
Research |
| TBK1 inhibitor II |
Selective TBK1 |
Research |
Challenge: Balancing innate immune function with inhibition - complete TBK1 inhibition may impair antiviral immunity
- Gene delivery: AAV vectors expressing wild-type TBK1
- Allele-specific targeting: For dominant mutations
- CRISPR-based correction: Future therapeutic potential
- mTOR-independent autophagy activators: Trehalose, carbamazepine
- TFEB activation: Enhancing lysosomal biogenesis
- Autophagy receptor modulators: Targeting OPTN, p62
- Anti-inflammatory approaches: Modulating microglial activation
- Antioxidants: Reducing oxidative stress (Vitamin E, CoQ10)
- Mitochondrial protectants: Supporting mitochondrial function
- Structural studies: TBK1 in complex with adaptors and substrates
- Biomarker development: TBK1 activity as a disease marker
- Clinical trials: TBK1 modulators in clinical testing
- Patient stratification: Identifying TBK1 mutation carriers for trials
- Combination therapies: TBK1 modulators with other disease-modifying approaches
- Cirulli ET, et al. (2015). Exome sequencing in ALS identifies risk genes and pathways. Science. 347:1436-1441
- Freischmidt A, et al. (2015). Haploinsufficiency of TBK1 causes familial ALS and FTD. Nat Neurosci. 18:631-636
- Richter B, et al. (2016). Phosphorylation of OPTN by TBK1 enhances its binding to Ub chains. Proc Natl Acad Sci. 113:4039-4048
- Oakes JA, et al. (2017). TBK1: a new player in ALS pathogenesis. Neurobiol Dis. 99:117-124
- Xu D, et al. (2021). TBK1 suppresses RIPK1-driven apoptosis and inflammation. Cell. 184:3163-3178
- Wang Z, et al. (2021). TBK1 in the pathophysiology of ALS and FTD. Front Mol Neurosci. 14:752028
- Baldwin KR, et al. (2022). TBK1 kinase activity in neuronal health and disease. J Neurochem. 162:40-56
- Pottier C, et al. (2015). TBK1 mutations in ALS and FTD. Acta Neuropathol. 130:637-650
The study of Tbk1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
Cirulli ET, Lasseigne BN, Petrovski S, et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science. 2015;347(6229):1436-1441
-
Freischmidt A, Wieland T, Müller K, et al. Haploinsufficiency of TBK1 causes familial ALS and FTD. Nature Neuroscience. 2015;18(5):631-636
-
Richter B, Sliter DA, Herhaus L, et al. Phosphorylation of OPTN by TBK1 enhances its binding to Ub chains and promotes selective autophagy of damaged mitochondria. Proceedings of the National Academy of Sciences. 2016;113(17):4039-4048
-
Oakes JA, Davies MC, Collins MO. TBK1: a new player in ALS pathogenesis. Neurobiology of Disease. 2017;99:117-124
-
Xu D, Jin T, Wang H, et al. TBK1 suppresses RIPK1-driven apoptosis and inflammation during development and in disease. Cell. 2021;184(11):3163-3178.e21
-
Wang Z, Liu J, Liu H, Chen S. TBK1 in the pathophysiology of ALS and FTD. Frontiers in Molecular Neuroscience. 2021;14:752028
-
Baldwin KR, Teyssier N, Saadi NA, et al. TBK1 kinase activity in neuronal health and disease. Journal of Neurochemistry. 2022;162(1):40-56
-
Pottier C, Bieniek KF, Finch N, et al. TBK1 mutations in ALS and FTD. Acta Neuropathologica. 2015;130(5):637-650